Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar
Tue, 12/06/2018 - 12:15
0 min
Español
0289.jpg
Download related document
Select rating
Give ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar 1/5
Give ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar 2/5
Give ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar 3/5
Give ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar 4/5
Give ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar 5/5
No votes yet
Related
ROVI Rating ESG 2020
0 min
25/09/2020
ROVI obtains second place in a global sustainability rating
ROVI participated voluntarily in this rating, which measures the sustainability of companies based on criteria such as corporate governance...
1 min
25/09/2020
Granting of partially refundable aid for the development of a new quarterly...
0 min
15/09/2020
See More
Email
Facebook
Twitter
LinkedIn
0289.jpg